Results 11 to 20 of about 3,120 (153)

Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort [PDF]

eJHaem
Introduction Real‐world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Methods We analysed efficacy and safety outcomes in patients ≥ 75 years from the French RetrosTECtive ...
A. Coste, S. Godet, S. Manier, J. R. Eveillard, C. Croizier, C. Mariette, C. Breal, H. Manjra, C. Touzeau, M. Mohty, R. Belkhir, A. Bobin, A. Lévêque, B. Cherel, L. Montes, F. Orsini‐Piocelle, L. Frenzel, D. Robu, E. Chalayer, S. Harel, L. Vincent, L. Bauschert, A. Dony, R. Tabrizi, P. Moreau, C. Hulin, A. Perrot   +26 more
doaj   +3 more sources

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study [PDF]

HemaSphere
Accelerated‐phase (AP) or blast‐phase (BP) myeloproliferative neoplasms (MPNs) are associated with dismal prognosis, with non‐curative therapies such as hypomethylating agents (HMAs) considered in patients not eligible for intensive therapy, while some ...
Corentin Orvain, Suzanne Tavitian, Clémence Mediavilla, Françoise Boyer, Alberto Santagostino, Geoffroy Venton, Samia Madene, Tony Marchand, Pascal Turlure, Diane Lara, Lenaig Le Clech, Katell Le Du, Jean‐Baptiste Robin, Lise Willems, Anaïse Blouet, Thomas Systchenko, Mathieu Wemeau, Hélène Pasquer, Mélanie Mercier, Christophe Nicol, Laurence Legros, Antoine Machet, Franck‐Emmanuel Nicolini, Lydia Roy, Clémentine Salvado, Guillaume Denis, Elsa Lestang, Kamel Laribi, Damien Luque Paz, Jean‐Jacques Kiladjian, Eric Lippert, Lina Benajiba, Jean‐Christophe Ianotto   +32 more
doaj   +3 more sources

TLX1 translocation variants and enhancer hijacking influence clinical outcome in T‐cell acute lymphoblastic leukemia [PDF]

HemaSphere
The T‐cell Leukemia Homeobox 1 (TLX1) oncogene is frequently deregulated in T‐cell acute lymphoblastic leukemia (T‐ALL) and T‐cell lymphoblastic lymphoma (T‐LBL).
Estelle Balducci, Thomas Steimlé, Agata Cieslak, Guillaume Charbonnier, Antoine Pinton, Mathieu Simonin, Charlotte Smith, Valentine Louis, Mélanie Féroul, Manon Delafoy, Sophie Kaltenbach, Audrey Bidet, Béatrice Grange, Lauren Rigollet, Patrick Villarese, Aurore Touzart, Hervé Dombret, André Baruchel, Nicolas Boissel, Vahid Asnafi   +19 more
doaj   +3 more sources

Evaluation externe de la qualité de la numération des lymphocytes T-CD4 au laboratoire d'immunologie et hématologie du CHU de Cocody

The Pan African Medical Journal, 2018
INTRODUCTION: Le taux de lymphocytes T-CD4 (LT4) est un paramètre crucial de suivi et de décision thérapeutique au cours de l'infection au Virus de l'Immunodéficience Humaine (VIH). Sa détermination doit être fiable et précise. Pour fournir des résultats
Koffi N’guessan, Yekayo Benedicte Koné, Oppong Richard Yéboah, Amah Patricia Goran-Kouacou, SérYRomuald Dassé   +4 more
doaj   +2 more sources

Hématologie du taureau N'Dama

Revue d’Elevage et de Médecine Vétérinaire des Pays Tropicaux, 1979
L'auteur rapporte les caractéristiques hématologiques notées lors de l'examen de 10 prélèvements de sang de taureaux N'Dama en provenance de la Côte-d'Ivoire.
L. Chevrier
doaj   +3 more sources

Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study [PDF]

eJHaem
The real‐life retrospective observational study CARMYN aimed at investigating the long‐term efficacy and safety of carfilzomib in combination with dexamethasone and lenalidomide (KRd, 159 patients). These patients (62% in first and 38% in second relapse,
Kamel Laribi, Xavier Leleu, Nathalie Texier, Raphaël Germain, Cyrille Touzeau, Mohammad Hammoud, Alexandre Payssot, Samantha Schulmann, Ronan Le Calloch, Adrien Trebouet, Driss Chaoui, Selva David, Omar Benbrahim, Riad Benramdane, Anne Charvet‐Rumpler, Christelle Jadeau, Eglantine Rouanet, Olivier Decaux, Aurore Perrot   +18 more
doaj   +2 more sources

Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study [PDF]

EJNMMI Research
Background Besides International Prognostic Index (IPI) score, baseline prognostic factors of post-transplant lymphoproliferative disorders (PTLD) are poorly identified due to the rarity of the disease.
David Morland, Lukshe Kanagaratnam, Fabrice Hubelé, Elise Toussaint, Sylvain Choquet, Aurélie Kas, Pierre-Ambroise Caquot, Corinne Haioun, Emmanuel Itti, Stéphane Leprêtre, Pierre Decazes, Fontanet Bijou, Paul Schwartz, Caroline Jacquet, Adrien Chauchet, Julien Matuszak, Nassim Kamar, Pierre Payoux, K-VIROGREF Study Group, Eric Durot   +19 more
doaj   +2 more sources

Epidemiological profile of constitutional thrombopathies in western Algeria [PDF]

Batna Journal of Medical Sciences, 2022
Introduction. As with all rare or orphan diseases, the study of inherited platelet disorders should be multicentric to identify as many or as few patients as possible in a given region or country. The aim of our study is to evaluate the prevalence of
Réda Messaoudi, Mohamed Amine Moueden, Hadj Touhami, Zahia Zouaoui, Naima Mesli, Abdelkader Adria   +5 more
doaj   +1 more source

Étude de la toxicité induite par le thiaméthoxame sur les paramètres morphologiques, hématologiques et sur l’équilibre oxydant/antioxydant chez des rats de souche Wistar [Study of the toxicity induced by thiamethoxam on morphological and hematological parameters and on the oxidant/antioxidant balance in Wistar rats]

Nutrition & Santé, 2022
Introduction. L’utilisation excessive des pesticides pose un véritable problème de santé publique, non seulement pour les personnes qui y sont exposées, mais aussi pour l’écosystème. Objectif.
Amal FEKI, Intissar KAMMOUN, Choumous KALLEL, Ahmed HAKIM, Ibtissem BEN AMARA   +4 more
doaj   +1 more source

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors. [PDF]

Hemasphere
HemaSphere, Volume 9, Issue 11, November 2025.
Stammler R, Chen P, Debeaupuis O, Zhao LP, Ruyer-Thompson M, Zakine E, Rossignol J, Goldwirt L, Comont T, Heiblig M, Adès L, Sebert M, Allain JS, Campagne J, Couturier MA, Cumin M, Dalmas MC, Denis G, Devloo C, De Voeght A, Drevon L, Duffau P, Georgin-Lavialle S, Gobert D, Kosmider O, Rieux-Laucat F, Abisror N, Lazaro E, Lopez JG, Maria A, Mauhin W, Merindol J, Merlot C, Mirault T, Pascal L, Perrin F, Raffoux E, Rahme R, Roos-Weil D, Terrier B, Thoreau B, Fain O, Fenaux P, Hirsch P, Jachiet V, Hadjadj J, Mékinian A, MINHEMON.   +47 more
europepmc   +2 more sources